SCHEMBL3375010

SCHEMBL3375010

CNC(=O)c1ccc(Oc2c(C)n(CC(=O)OC)c3ccc(Cl)cc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 9/20 0.57
AKR1B1 P15121 1/20 0.43
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PTGS2 P35354 3/20 0.42
CNR2 P34972 1/20 0.42
AKR1C3 P42330 1/20 0.42
MMP13 P45452 1/20 0.41
MAPT P10636 3/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
HK1 P19367 1/20 0.39
HKDC1 Q2TB90 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
PLK1 P53350 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373960 0.91 PTGDR2 (0.70) PTGDR2AKR1B1HPGDTSHRHTT
SCHEMBL3370516 0.90 PTGDR2 (0.55) PTGDR2AKR1B1PTGS2CNR2AKR1C3
SCHEMBL3374154 0.90 PTGDR2 (0.55) PTGDR2AKR1B1PTGS2CNR2AKR1C3
SCHEMBL3369841 0.90 PTGDR2 (0.59) PTGDR2AKR1B1HPGDTSHRHTT
SCHEMBL2052563 0.81 PTGDR2 (0.71) PTGDR2AKR1B1TSHRPTGS2AKR1C3
SCHEMBL3374906 0.81 PTGDR2 (0.54) PTGDR2AKR1B1TSHRPTGS2CNR2
SCHEMBL2031573 0.81 PTGDR2 (0.67) PTGDR2AKR1B1PTGS2
SCHEMBL3373433 0.81 PTGDR2 (0.67) PTGDR2AKR1B1
SCHEMBL3372375 0.80 PTGDR2 (0.72) PTGDR2AKR1B1HPGDTSHRHTT
SCHEMBL3372368 0.80 PTGDR2 (0.76) PTGDR2AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656347-B1 SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2010-10-13 EP disclosed
US-7709521-B2 Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-20060264444-A1 Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases ASTRAZENECA AB (SE) 2006-11-23 US disclosed
EP-1656347-A1 SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES Astrazeneca AB (SE) 2006-05-17 EP disclosed
WO-2005019171-A1 SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264444-A1 Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases IDO1, IDO2, TPH1 PTGDR2 303/4885AKR1B1 296/4885HPGD 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.